Cargando…
Pasireotide Therapy of Multiple Endocrine Neoplasia Type 1–Associated Neuroendocrine Tumors in Female Mice Deleted for an Men1 Allele Improves Survival and Reduces Tumor Progression
Pasireotide, a somatostatin analog, is reported to have anti-proliferative effects in neuroendocrine tumors (NETs). We therefore assessed the efficacy of pasireotide for treating pancreatic and pituitary NETs that develop in a mouse model of multiple endocrine neoplasia type 1 (MEN1). Men1(+/−) mice...
Autores principales: | Walls, Gerard V., Stevenson, Mark, Soukup, Benjamin S., Lines, Kate E., Grossman, Ashley B., Schmid, Herbert A., Thakker, Rajesh V. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Endocrine Society
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4870877/ https://www.ncbi.nlm.nih.gov/pubmed/26990064 http://dx.doi.org/10.1210/en.2015-1965 |
Ejemplares similares
-
Multiple endocrine neoplasia type 1
por: Thakker, R. V.
Publicado: (2012) -
Gastroenteropancreatic Neuroendocrine Tumors in Multiple Endocrine Neoplasia Type 1
por: Tonelli, Francesco, et al.
Publicado: (2012) -
Multiple endocrine neoplasia type 1 (MEN1) and type 4 (MEN4)
por: Thakker, Rajesh V.
Publicado: (2014) -
Thymic neuroendocrine tumors in patients with multiple endocrine neoplasia type 1
por: Yliaska, Iina, et al.
Publicado: (2022) -
Multiple Endocrine Neoplasia Type 1 (MEN1) Phenocopy Due to a Cell Cycle Division 73 (CDC73) Variant
por: Lines, Kate E, et al.
Publicado: (2020)